Inhaled Dry Powder Antibiotics in Patients with Non-Cystic Fibrosis Bronchiectasis: Efficacy and Safety in a Real-Life Study.
bronchiectasis
colistin
dry-powder antibiotics
inhaled antibiotics
pseudomonas aeruginosa
tobramycin
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
21 Jul 2020
21 Jul 2020
Historique:
received:
15
06
2020
revised:
13
07
2020
accepted:
15
07
2020
entrez:
26
7
2020
pubmed:
28
7
2020
medline:
28
7
2020
Statut:
epublish
Résumé
Nebulised antibiotics are habitually used in patients with bronchiectasis, but the use of dry powder inhaled antibiotics (DPIA) in these patients is extremely limited. This study seeks to analyse the efficacy and safety of DPIA in bronchiectasis patients. Multi-centre study of historic cohorts. All the hospital centres in Spain were contacted in order to collect data on patients with a diagnosis of bronchiectasis who had taken at least one dose of DPIA. Its efficacy was analysed in clinical, functional and microbiological terms by comparing the year before and the year after the prescription of DPIA. Adverse effects and variables associated with these effects, or any need to withdraw the drug, were also analysed. 164 patients from 33 Spanish centres were included; 86% and 14% of these were treated with dry powder colistin and tobramycin, respectively. Chronic bronchial infection by Our study suggests that DPIA are clinically efficacious and safe for treating bronchiectasis patients. Cough was shown to be the most common side-effect and reason for withdrawal of the treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Nebulised antibiotics are habitually used in patients with bronchiectasis, but the use of dry powder inhaled antibiotics (DPIA) in these patients is extremely limited. This study seeks to analyse the efficacy and safety of DPIA in bronchiectasis patients.
MATERIAL AND METHODS
METHODS
Multi-centre study of historic cohorts. All the hospital centres in Spain were contacted in order to collect data on patients with a diagnosis of bronchiectasis who had taken at least one dose of DPIA. Its efficacy was analysed in clinical, functional and microbiological terms by comparing the year before and the year after the prescription of DPIA. Adverse effects and variables associated with these effects, or any need to withdraw the drug, were also analysed.
RESULTS
RESULTS
164 patients from 33 Spanish centres were included; 86% and 14% of these were treated with dry powder colistin and tobramycin, respectively. Chronic bronchial infection by
CONCLUSIONS
CONCLUSIONS
Our study suggests that DPIA are clinically efficacious and safe for treating bronchiectasis patients. Cough was shown to be the most common side-effect and reason for withdrawal of the treatment.
Identifiants
pubmed: 32708262
pii: jcm9072317
doi: 10.3390/jcm9072317
pmc: PMC7408283
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Sociedad Española de Neumologia SEPAR
ID : 010.2018
Références
Arch Bronconeumol. 2018 Feb;54(2):88-98
pubmed: 29128129
Respir Med. 2000 Jul;94(7):632-40
pubmed: 10926333
Curr Opin Pulm Med. 2014 Nov;20(6):607-12
pubmed: 25221853
Eur Respir J. 2017 Sep 9;50(3):
pubmed: 28889110
Multidiscip Respir Med. 2016 Jun 08;11:21
pubmed: 27280021
Drugs. 2014 Mar;74(3):377-87
pubmed: 24510624
Pharmacy (Basel). 2018 Sep 29;6(4):
pubmed: 30274303
Adv Respir Med. 2018;86(1):44-52
pubmed: 29490421
J Cyst Fibros. 2015 Jan;14(1):111-9
pubmed: 25091537
Int J Mol Sci. 2017 May 16;18(5):
pubmed: 28509852
Eur Respir J. 2014 May;43(5):1357-67
pubmed: 24232697
Eur Respir J. 2018 Jan 25;51(1):
pubmed: 29371384
Chest. 1998 May;113(5):1329-34
pubmed: 9596315
Chest. 1995 Feb;107(2 Suppl):65S-70S
pubmed: 7842816
Eur Respir J. 2013 May;41(5):1107-15
pubmed: 23018904
Arch Bronconeumol. 2020 Feb 17;:
pubmed: 32081438
Arch Bronconeumol. 2018 Feb;54(2):79-87
pubmed: 29128130
Lancet Respir Med. 2014 Sep;2(9):738-49
pubmed: 25154045
Thorax. 2013 Apr;68(4):344-50
pubmed: 23135343
Eur Respir J. 2018 Jan 25;51(1):
pubmed: 29371383
Antimicrob Agents Chemother. 2020 Feb 21;64(3):
pubmed: 31964790
PLoS One. 2016 Mar 09;11(3):e0149768
pubmed: 26959239
J Cyst Fibros. 2007 Jul;6(4):284-92
pubmed: 17185047
Lancet Respir Med. 2020 Jan;8(1):12-14
pubmed: 31570316
BMJ Open Respir Res. 2018 Dec 28;5(1):e000348
pubmed: 30687502